Study summary
Adding trabectedin to doxorubicin extended survival in leiomyosarcoma by about 9 months
33 momedian survival, vs 24 months with doxorubicin alone
What was tested
Doxorubicin plus trabectedin, followed by trabectedin maintenance, against doxorubicin alone, as first treatment for advanced or metastatic leiomyosarcoma of the uterus or soft tissue.
What they found
- Median survival was 33 vs 24 months (hazard ratio 0.65).
- Time before the cancer grew doubled: 12 vs 6 months.
- Side effects and dose reductions were more common with the combination.
What it means
The first combination in decades to beat doxorubicin alone on survival in a sarcoma subtype.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.